吉林大学学报(医学版)

• 基础研究 • 上一篇    下一篇

自身免疫性肝炎/原发性胆汁性肝硬化重叠综合征患者临床特征分析

刘 晨1,徐长妍2,李国东3,迟宝荣4    

  1. 1.哈尔滨医科大学附属第二医院消化内科,黑龙江 哈尔滨 150086;2.吉林大学第一医院病案室,吉林 长春 130021;3.哈尔滨医科大学附属第四医院肿瘤外科,黑龙江 哈尔滨 150001;4.吉林大学第一医院消化内科,吉林 长春 130021
  • 收稿日期:2013-06-08 出版日期:2014-05-28 发布日期:2014-06-05
  • 通讯作者: 迟宝荣 (Tel:0431-85612437,E-mail:chibr@jlu.edu.cn ) E-mail:chibr@jlu.edu.cn
  • 作者简介:刘 晨 (1978-),女,黑龙江省哈尔滨市人,主治医师,医学博士,主要从事肝病及消化道肿瘤基础和临床方面的研究
  • 基金资助:

     国家自然科学基金资助课题(81302059)

Analysis of clinical features  of patients with autoimmune hepatitis/primary biliary cirrhosis overlap syndrome

LIU  Chen1, XU Chang-yan2,LI  Guo-dong3,CHI Bao-rong4   

  1. 1. Department of Digestive Diseases,Second Affiliated Hospital,Harbin Medical University,Harbin150086,China;2.Department of Medical Record,First Hospital,Jilin University,Changchun 130021,China;3.Department of Surgical Oncology,Fourth Affiliated Hospital,Harbin Medical U
    niversity,Harbin 150001,China;4.Department of Digestive Diseases,First Hospital,Jilin University,Changchun 130021,China
  • Received:2013-06-08 Online:2014-05-28 Published:2014-06-05

摘要:

目的:比较自身免疫性肝炎(AIH)和胆汁性肝硬化(PBC)与AIH/PBC重叠综合征患者的生物化学、免疫学指标及病理组织学特点,为制定AIH/PBC重叠综合征临床诊断的参考标准及合理的治疗方案提供依据。方法:选取135例自身免疫性肝病患者,其中AIH患者49例、PBC患者43例、AIH/PBC重叠综合征患者43例,检测各类型患者的生物化学、免疫学和组织病理学等指标,并对AIH/PBC患者行不同的治疗方案,分别给予患者熊去氧胆酸、泼尼松及熊去氧胆酸和泼尼松联合治疗,评价各治疗方案的有效性。结果:生化指标,AIH/PBC组患者γ-谷氨酰转移酶(GGT)、碱性磷酸酶(ALP)活性和IgM水平显著高于AIH组(P<0.05), AIH/PBC组患者的丙氨酸转氨酶(ALT)、谷草转氨酶(AST)活性和IgG水平显著高于PBC组(P<0.05)。自身抗体指标,与AIH组比较,AIH/PBC组患者抗线粒体抗体(AMA)和M2型线粒体抗体(AMA M2)检出率增高(P<0.05);与PBC组比较,AIH/PBC组患者抗核抗体(ANA)和抗平滑肌抗体(SMA)检出率增高(P<0.05)。病理学检查,AIH/PBC组患者存在高发生率的碎屑样坏死(100.00%)、肝细胞玫瑰花环样改变(83.72%)及胆管病变(69.77%)。对AIH/PBC患者实施联合用药组有效率为85.7%,显著于各种单独用药组(P<0.05)。结论:AIH/PBC重叠综合征患者的生物化学、免疫学指标和病理组织学变化兼有AIH和PBC患者的特点,因此可以作为其诊断依据。泼尼松联合熊去氧胆酸治疗AIH/PBC综合征取得了较好的疗效,值得临床推广。

关键词: 肝硬化, 胆汁性, 肝炎, 自身免疫性, 重叠综合征

Abstract:

Objective To compare the biochemical and  immunological parameters and histopathological characteristics  in the patients with autoimmune hepatitis
 (AIH),biliary cirrhosis (PBC) and AIH/PBC overlap syndrome,and to provide basis for working out the reference standard of clinical diagnosis and reasonable treatment. Methods 135 cases of autoimmune liver disease patients were selected,including 49 cases of AIH patients,43 cases of PBC patients,and 43 cases of AIH/PBC overlap syndrome  patients.The biochemical,immunological parameters and histopathological changes of the patients were dete
cted.The patients  with  AIH / PBC overlap syndrome were treated with different therapy methods including ursodesoxycholic acid(UDCA) treatment,prednisone treatment and combination treatment with UDCA and prednisone,and   the effectiveness of different treatment programs were evaluated.Results The activities  of  GGT and ALP and IgM level of the patients in the AIH/PBC group were significantly higher than those in   AIH group,there were significant differences (P<0.05);the activities of ALT and AST and IgG level of the patients in  AIH/PBC group was significantly higher than those in  PBC group,there were significant differences (P<0.05).The detection rates of AMA and AMA M2 of the patients in AIH/PBC group were higher than those in AIH group,there were significant differences (P<0.05);the detection rates of ANA and SMA of the patients in AIH/PBC group were higher than those in PBC group,there were significant differences (P<0.05).There were high incidence of piecemeal necrosis (100.0%),liver cell rosette-like changes (83.72%) and bile duct lesions (69.77%) of the patients in AIH/PBC group.The effective percentage in combination therapy group was 85.7% which was significantly higher than those in various drug alone groups (P<0.05).Conclusion The changes of biochemical and immunological indicators  and pathological features of the patients with   AIH/PBC overlap syndrome are in  combination with the particular indicators of AIH and PBC which  would provide the diagnostic basis for AIH/PBC overlap syndrome.The combined therapy for AIH/PBC overlap syndrome is effective and should be popularized.

Key words: liver cirrhosis, biliary;hepatitis, autoimmune;overlap syndrome

中图分类号: 

  • R575.2